evipedia.ai
← Back

Kaempferol for Health & Longevity

Evidence Review created on 09/13/2026 using AI4L / Opus 5

Also known as: 3,4’,5,7-Tetrahydroxyflavone, Kaempherol, Kempferol, Robigenin, Trifolitin, Populnetin, Swartziol, Rhamnolutein, Indigo Yellow

Motivation

Kaempferol is a yellow plant pigment present in kale, capers, tea, broccoli, beans, endive and onions. Most people consume a few milligrams of it daily without noticing. Interest in it as a concentrated supplement is recent, driven by laboratory work suggesting it helps muscle cells generate energy when oxygen is scarce and calms the low-grade inflammation that accumulates with age.

The compound carries the name of a seventeenth-century German naturalist and was first isolated from a garden flower more than a century ago, yet it spent most of that time as a plant-chemistry curiosity rather than a candidate supplement. That changed once large population surveys began linking diets richer in it to slower mental decline and lower death rates, and once a small number of human trials tested a purified oral form directly.

This review examines what is known about kaempferol taken as a supplement rather than eaten in food: how much reaches the bloodstream, what the human trials measured and who funded them, where the evidence remains confined to cells and animals, and what the safety record covers.

Benefits - Risks - Protocol - Conclusion

High-level sources that frame kaempferol as a whole rather than reporting a single mechanism.

No content from the six priority platforms is listed: searches of all six returned either nothing or only passing keyword matches inside articles about other compounds, and padding the list with those would not meet the bar of discussing kaempferol in substantial depth.

Grokipedia

  • Kaempferol

    Useful for chemistry, naming history and food-content figures, including the estimate that United States adults consume roughly 5.4 mg daily from a balanced diet.

Examine

  • Kaempferol

    States plainly that supplemental human research is scarce while laboratory work looks promising, and records that the site’s detailed research breakdown has been archived.

ConsumerLab

No ConsumerLab article or product review for kaempferol exists. The term surfaces only inside reviews of other products, such as the Ginkgo biloba supplements review, where kaempferol is one of the marker flavonols tested for.

Systematic Reviews

Pooled evidence on kaempferol, spanning human observational data and preclinical models.

The claimed-benefit side of the trade-off is represented above; the risk side is unrepresented, because no systematic review or meta-analysis of kaempferol’s harms, toxicity or adverse events exists on PubMed as of 13 September 2026.

Mechanism of Action

Kaempferol carries hydroxyl groups at four ring positions but, unlike quercetin, lacks an adjacent pair on its outer ring. So it is not a substrate for COMT (catechol-O-methyltransferase, which inactivates two-hydroxyl plant compounds), leaving glucuronidation by UGT1A1 and UGT1A9 and sulfation by SULT1A1 (gut and liver enzymes that tag compounds for excretion) as its only conjugation routes.

Three actions dominate. It activates Nrf2 (nuclear factor erythroid 2-related factor 2, the master switch for a cell’s own antioxidant genes) while suppressing NF-κB (nuclear factor kappa B, the principal inflammatory signalling switch), lowering cytokine output. In human muscle cells it raises cyclic AMP (a universal internal messenger) and protein kinase A (its signal-relaying enzyme), inducing PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha, the master regulator of mitochondrial construction) and type 2 iodothyronine deiodinase (which converts thyroid hormone to its active form); oxygen consumption rises roughly 30% (da-Silva et al., 2007). It also interferes with topoisomerase II (which unknots DNA during cell division).

A competing reading holds the effect is hormetic, not antioxidant: plasma concentrations after an oral dose are far too low for direct scavenging, so benefit arises from a mild stress that upregulates endogenous defences and reverses higher up (Calabrese et al., 2025).

It is multi-target, not receptor-selective. Plasma peaks near 5.8 hours, almost entirely as kaempferol-3-glucuronide, with no conversion to quercetin and about 2% recovered in urine by 24 hours (DuPont et al., 2004). Animal work shows wide tissue distribution, limited brain entry. No human terminal half-life has been published.

Historical Context & Evolution

Kaempferol was never developed for a medical purpose. It is named after Engelbert Kaempfer, the seventeenth-century German naturalist whose name also marks the plant genus Kaempferia, and it was first isolated in 1902 from forking larkspur (Delphinium consolida) by the chemists A. G. Perkin and E. J. Wilkinson. Its original use was as a plant pigment and a reference compound in textile dye chemistry, which is why one of its older names is indigo yellow.

Its move into health research came indirectly, through the flavonol class. The Zutphen Elderly Study in 1993 reported an inverse association between dietary flavonol intake and coronary heart disease (Hertog et al., 1993), after which epidemiological cohorts began quantifying kaempferol separately from quercetin and myricetin. Human absorption work then produced a genuinely surprising result: kaempferol is absorbed more efficiently than quercetin even at low oral doses, the opposite of what its lower food abundance implied (DuPont et al., 2004).

The framing has shifted twice since. Throughout the 2000s and 2010s the compound was studied overwhelmingly as an antioxidant and anticancer agent in cell culture. That interpretation has not been discredited so much as bounded: the pro-oxidant and hormetic findings at higher concentrations, and the low plasma levels measured in people, argue that direct scavenging cannot be the operative mechanism, while the anti-inflammatory signalling data survived. From 2023 onward a Japanese manufacturer reframed it again, as an oxygen-utilisation aid tested in exercise and sleep trials rather than as an antioxidant.

Expected Benefits

High 🟩 🟩 🟩

Reduced Cardiopulmonary Cost of Strenuous Exercise

A single 10 mg oral dose lowers the oxygen and heart-rate cost of a fixed workload and extends time to exhaustion. The proposed mechanism is improved mitochondrial oxygen utilisation under low-oxygen conditions, first observed in cultured muscle cells. Two randomised, double-blind, placebo-controlled crossover trials in trained male athletes support it: one using constant-load tests (Okita et al., 2025), one using consecutive 400 m runs, where muscle-damage markers also fell (Okita et al., 2024). Both were small, single-sex and acute-dose, run by Otsuka Pharmaceutical, which sells the compound.

Magnitude: Oxygen uptake fell by 1.4, 1.0 and 0.9 mL·kg⁻¹·min⁻¹ at 25%, 50% and 75% of maximal aerobic capacity and respiratory rate by 1.9, 1.8 and 2.0 breaths per minute, while time to exhaustion at maximal capacity lengthened by 20 seconds, each at p < 0.05 (a result unlikely to arise by chance) against placebo.

Medium 🟩 🟩

Slower Global Cognitive Decline at Higher Dietary Intake

Older adults with higher habitual kaempferol intake declined more slowly across a standardised battery of thinking tests over an average of 6.9 years, as did four individual cognitive domains. The proposed basis is reduced brain inflammation and oxidative damage. Evidence is one prospective cohort of 961 community-dwelling adults with repeated annual testing, adjusted for age, education, APOE4 status (a gene variant that raises dementia risk) and lifestyle (Holland et al., 2023). Intake came from food questionnaires, so kaempferol cannot be separated from the vegetables carrying it.

Magnitude: Higher daily kaempferol intake was associated with slower annual decline in global cognition, β = 0.01 (β is the regression coefficient, here the change in decline rate per unit of intake; 95% confidence interval, the range in which the true value most likely falls: 0.006–0.02) — the largest estimate among the four flavonols examined.

Lower All-Cause Mortality at Higher Dietary Intake

Higher kaempferol intake tracked with fewer deaths from any cause and from cancer in a nationally representative United States sample followed for a median of 7.8 years. The proposed basis is the same anti-inflammatory and antioxidant signalling invoked elsewhere. Evidence is one large prospective cohort of 11,679 adults with dietary recall data and death-registry linkage, adjusted for demographic, metabolic and lifestyle covariates (Zong et al., 2024). Single 24-hour recalls are a weak intake proxy, and the whole flavonol class moved together, so the signal is not kaempferol-specific.

Magnitude: Hazard ratio (the ratio of event rates between higher and lower intake groups) 0.74, 95% confidence interval 0.63–0.86, for all-cause mortality; 0.62, 0.40–0.97, for cancer mortality. No association appeared for diabetes-specific mortality.

Lower Cardiovascular Disease Incidence at Higher Dietary Intake

Kaempferol intake was inversely and linearly associated with cardiovascular disease across pooled prospective cohorts, the flavonol class as a whole tracking with coronary heart disease. The proposed mechanisms are improved endothelial function, reduced oxidation of circulating lipoproteins and suppressed vascular inflammation. Evidence is a dose-response meta-analysis of 39 prospective cohorts comprising 1,501,645 individuals and 33,637 cardiovascular events, with kaempferol analysed as an individual compound (Micek et al., 2021). All constituent data are observational, and flavonol-rich diets differ from flavonol-poor diets in many other ways.

Magnitude: A linear inverse association between increasing kaempferol intake and cardiovascular disease risk, holding across the habitual intake range covered by 1,501,645 pooled participants and 33,637 cardiovascular events; the published report gives kaempferol’s result as a linear trend and no outcome figure for the compound itself.

Improved Sleep Quality and Spontaneous Daily Activity

Two weeks of 10 mg daily lowered heart rate at every activity level, raised mean daily step count and distance covered, and improved the wearable’s sleep score. The proposed mediator is a shift toward parasympathetic dominance, reflected in a rise in a beat-to-beat heart-rate variability measure. Evidence is one randomised, double-blind, placebo-controlled crossover trial in 33 office workers of both sexes wearing accelerometer-based monitors almost continuously (Ikeda et al., 2024). Otsuka Pharmaceutical ran the trial, and sleep quality came from the wearable’s own sleep score, not a sleep laboratory.

Magnitude: Against placebo over two weeks at 10 mg daily, heart rate fell by 4, 3 and 2 beats per minute during light, moderate and vigorous activity and by 6 during sleep and rest, mean daily step count rose by 624 steps and distance covered by 0.4 km, and the sleep-quality score rose by 3.9 points.

Low 🟩

Lower Cancer Incidence at Higher Dietary Intake ⚠️ Conflicted

Higher intake tracks with fewer cancers in some cohorts, none in others: pooled data show lower lung cancer odds (Rostampour et al., 2025) and a nurses’ cohort lower ovarian incidence (Gates et al., 2007), while a 38,408-woman cohort found none (Wang et al., 2009). No causal claim is supportable.

Magnitude: Pooled odds ratio (the ratio of the odds of disease between highest and lowest intake) 0.78, 95% confidence interval 0.64–0.96, for lung cancer; relative risk (the ratio of risks between those groups) 0.60, 0.42–0.87, for ovarian cancer. The null cohort reported relative risks near 1.00 at every site, and the large laboratory literature on tumour-cell apoptosis has never been tested in people.

Four weeks of 10 mg daily reduced frequency, duration and severity of headache attributed to falling barometric pressure. Proposed mechanism: better oxygen utilisation plus autonomic rebalancing. Evidence is a single-arm, open-label pilot with no control group, so expectancy and regression to the mean are unexcluded (Ikeda et al., 2025).

Magnitude: Headache frequency improved with Cohen’s d (a standardised measure of how large a change is relative to its spread) of 0.61, severity 0.57, and duration a rank-biserial correlation (a rank-based measure of how consistently one condition outperforms the other) of 0.64, with over 80% of 387 analysed participants reporting improvement.

Speculative 🟨

Clearance of Senescent Cells and Extension of Healthspan

No human outcome data exist. The claim rests on biphasic dose-response curves in cell models, lifespan extension in fruit flies and nematodes, and mitophagy (damaged-mitochondria recycling) effects in aged mice (Calabrese et al., 2025).

Suppression of Joint Inflammation and Cartilage Breakdown

Basis is preclinical only: pooled rodent and cell-culture arthritis models showing lower arthritis scores, reduced inflammatory cytokines and suppressed cartilage-degrading enzymes (Nazir et al., 2025). No controlled human arthritis study has been conducted.

Neuroprotection After Ischaemic Stroke

Animal models only. Rodent stroke studies consistently report smaller infarcts through antioxidant, anti-inflammatory and anti-apoptotic routes, and the authors state clinical confirmation has not been attempted (Shadman et al., 2025).

Antidepressant-Like Effects

Rodent behavioural models only. A network meta-analysis of forced-swim, tail-suspension and sucrose-preference tests found kaempferol active but weaker than fluoxetine on most endpoints (Lei et al., 2025).

Improved Glucose Tolerance and Insulin Sensitivity

Rodent and cell work only. Kaempferol cut fat mass and corrected glucose tolerance and insulin resistance in obese mice via adipose-tissue inflammatory signalling (Zhai et al., 2024). No human glycaemic endpoint has been measured.

Preservation of Bone Density

Rodent and cell work only. Kaempferol promoted bone formation and suppressed bone resorption across in vivo and in vitro models (Wong et al., 2019). Human data exist only for a locally applied gel.

Protection Against Liver Injury and Fibrosis

Animal and cell work only. Kaempferol reduced oxidative and inflammatory liver damage across models of alcoholic liver disease, fatty liver, fibrosis and liver cancer (Xiao et al., 2022). No human liver endpoint has been measured.

Benefit-Modifying Factors

  • Conjugation-enzyme genotype: UGT1A1, UGT1A9 and SULT1A1 activity determines how fast kaempferol is cleared, and reduced-function variants of each are common; slow conjugators hold higher plasma levels from the same oral dose for longer.

  • Efflux-transporter genotype: ABCG2 (which codes the pump that ejects flavonols back into the gut lumen) shows a common reduced-function variant. Carriers absorb more from an identical dose, widening the sevenfold between-person spread already documented in human absorption work.

  • Baseline inflammatory and metabolic markers: Those starting with elevated high-sensitivity C-reactive protein, raised fasting glucose or poor heart-rate variability have more room to move. The exercise trials recruited already-trained athletes, and benefit in sedentary populations is untested.

  • Sex: The two exercise trials enrolled men only. The crossover trial of sleep and activity included 16 women of 33 participants without reporting sex-stratified results, so female-specific effect sizes remain unestablished for every endpoint.

  • Pre-existing conditions: Thyroid disease, iron deficiency and hormone-receptor-positive cancers all intersect with kaempferol’s known actions. Conversely, established cardiometabolic disease or early cognitive decline is where the observational signal is largest.

  • Age: The cognition and mortality cohorts enrolled adults aged 60 and above, where absolute event rates make benefit detectable. The safety trial spanned ages 20 to 79, but the efficacy trials enrolled only young trained athletes and working-age adults.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: replicated human adverse-event data do not exist, the entire controlled record being one 4-week randomised trial at 50 mg daily plus three small short-duration exercise and behaviour trials, none of which recorded a treatment-related adverse event.

Medium 🟥 🟥

No risk reaches Medium either: there is no single controlled trial and no consistent observational dataset reporting a kaempferol-attributable adverse outcome, haematology, blood biochemistry, urinalysis, anthropometry and blood pressure all being unchanged against placebo in the one safety trial (Akiyama et al., 2023).

Low 🟥

Reduced Absorption of Non-Heme Iron

Flavonols bind non-heme iron in the gut and block its uptake. Evidence is indirect human data: radio-iron absorption studies using polyphenol-rich beverages, not isolated kaempferol (Hurrell et al., 1999). Relevant chiefly to menstruating women, frequent blood donors and endurance athletes; fully reversible by separating doses from meals.

Magnitude: Beverages supplying 20–50 mg of total polyphenols with a meal reduced non-heme iron absorption by 50–70%, and 100–400 mg by 60–90%; no study has measured the effect of isolated kaempferol at supplemental doses.

Blunted Adaptation to Endurance Training

Antioxidant supplementation taken chronically around training can suppress the redox signalling that drives mitochondrial adaptation. Evidence is indirect: an 11-week randomised trial of vitamin C and E, not kaempferol (Paulsen et al., 2014). Whether a 10 mg flavonol dose is sufficient to do this is untested and plausibly not.

Magnitude: In that trial, training-induced rises in two muscle mitochondrial-biogenesis markers were abolished (cytochrome c oxidase subunit IV: +59% on placebo versus −13% on antioxidants; PGC-1α: +19% versus −13%, p ≤ 0.03), while maximal oxygen uptake gains were unaffected at 8% in both groups.

Speculative 🟨

Chromosomal Breaks in Blood-Forming Progenitor Cells

No human data. At dietary-relevant concentrations kaempferol induced double-strand breaks and translocations in human CD34+ (blood-forming) progenitors, resembling infant leukaemia rearrangements (Barjesteh van Waalwijk van Doorn-Khosrovani et al., 2007), largely topoisomerase-II-independent (Goodenow et al., 2020).

Activation of Thyroid Hormone and Raised Energy Expenditure

Isolated human muscle cells only. Kaempferol raised the activity of the enzyme converting thyroid hormone to its active form roughly tenfold and active-hormone production 2.6-fold, persisting 24 hours after removal (da-Silva et al., 2007).

Oestrogen-Receptor Activity in Hormone-Sensitive Tissue

Cell and animal work only. Kaempferol binds both oestrogen receptors weakly, and a kaempferol glycoside promoted ovarian function while acting against breast cancer cells (Harrath et al., 2021). No human hormonal endpoint has been measured.

Pro-oxidant Effects Above the Hormetic Dose Range

No human data. The same integrated dose-response analysis that supports benefit at low concentrations documents reversal and cellular harm at higher ones, the inverted-U being the rule rather than the exception (Calabrese et al., 2025).

Inhibition of Platelet Aggregation and Prolonged Bleeding

Animal and cell work only. Kaempferol blocked two clotting enzymes, thrombin and factor Xa, delayed collagen-induced aggregation by 34.6% and prevented experimental clots in rodents (Choi et al., 2015). No human bleeding endpoint exists.

Risk-Modifying Factors

  • Conjugation and transporter genotype: Reduced-function UGT1A1, SULT1A1 or ABCG2 variants raise systemic exposure from the same oral dose, shifting a person further along the hormetic curve toward its descending limb where effects reverse.

  • Baseline iron and thyroid markers: Low ferritin or transferrin saturation makes the iron-absorption effect consequential rather than academic. A suppressed thyroid-stimulating hormone or a free triiodothyronine near the top of range makes thyroid activation the relevant concern.

  • Sex: Menstruating women carry the greater iron-absorption risk and lower baseline iron stores. No sex-stratified adverse-event data exist from any kaempferol trial, and the two exercise trials enrolled men exclusively.

  • Pre-existing conditions: Hormone-receptor-positive cancers, treated hypothyroidism, iron-deficiency anaemia, bleeding disorders and significant hepatic or renal impairment each intersect with a documented or plausible kaempferol action.

  • Age: Older adults carry more polypharmacy, so the transporter and enzyme interactions matter more; they also have lower gastric acid output and reduced renal clearance. Only the 4-week safety trial enrolled adults past 60, recording no adverse events.

Key Interactions & Contraindications

  • CYP3A4 substrates (simvastatin, tacrolimus, ciclosporin): Caution. Kaempferol inhibits CYP3A4 (the liver’s main drug-metabolising enzyme) yet induces it via PXR (a drug-metabolism gene switch), so exposure may rise or fall (Li et al., 2022; Liu et al., 2006). Separate by 4 hours; monitor levels.

  • P-glycoprotein and BCRP substrates (digoxin, nifedipine, rosuvastatin): Caution, risk of raised drug levels and toxicity. Kaempferol inhibits both efflux pumps (BCRP is breast cancer resistance protein, a drug-ejecting pump), increasing nifedipine exposure in rats (Park & Choi, 2019). Mitigation: avoid co-dosing with narrow-margin substrates.

  • Anticoagulants and antiplatelets (warfarin, apixaban, clopidogrel, aspirin): Caution, increased bleeding risk from additive platelet inhibition by flavonols. Mitigation: check the international normalised ratio within 1–2 weeks of starting and avoid entirely if that value is unstable.

  • Levothyroxine and antithyroid agents (methimazole, propylthiouracil): Monitor. Kaempferol upregulates the enzyme that activates thyroid hormone, so replacement or suppression may become mis-dosed. Mitigation: separate oral doses by 4 hours and recheck thyroid panel at 6–8 weeks.

  • Endocrine cancer therapy (tamoxifen, anastrozole, letrozole): Absolute contraindication during active treatment. Kaempferol has weak oestrogen-receptor activity and inhibits the sulfotransferase enzymes that clear oestrogens, so it may oppose the therapeutic intent.

  • Topoisomerase-II-targeted chemotherapy (etoposide, doxorubicin, mitoxantrone): Absolute contraindication. Kaempferol acts on the same enzyme and causes double-strand breaks in progenitor cells, so additive genotoxicity cannot be excluded and no interaction study exists.

  • Oral iron salts (ferrous sulfate, ferrous bisglycinate) and iron-rich meals: Caution, reduced iron absorption and blunted repletion. Mitigation: take kaempferol at least 2 hours away from iron doses and from the largest plant-iron meal of the day.

  • Glucose-lowering agents (metformin, glimepiride, insulin): Monitor for hypoglycaemia. Kaempferol lowers blood glucose in rodent models through insulin-sensitising and hepatic routes. Mitigation: check fasting glucose weekly for the first month in anyone on a sulfonylurea (an insulin-releasing tablet class) or insulin.

  • Other flavonoid and polyphenol supplements (quercetin, fisetin, luteolin, myricetin, epigallocatechin gallate, curcumin): Caution, additive exposure and bleeding risk. All compete for the same conjugating enzymes and efflux pumps and all inhibit platelet aggregation. Mitigation: avoid stacking more than one flavonol.

  • Other interventions: Caution with high-dose fish oil and with nitric-oxide-boosting supplements such as beetroot nitrate, because the additive antiplatelet and haemodynamic effects compound those of kaempferol during strenuous exercise.

Populations who should avoid Kaempferol:

  • Pregnancy and breastfeeding, given documented translocation formation in human fetal-type CD34+ progenitors at dietary concentrations
  • Anyone on warfarin with an unstable or supratherapeutic international normalised ratio (above 3.5, or fluctuating by more than 1.0 between checks)
  • Active hormone-receptor-positive breast, ovarian or endometrial cancer, and anyone on endocrine therapy for it
  • Current topoisomerase-II-targeted chemotherapy, or within 30 days of its completion
  • Diagnosed iron-deficiency anaemia (ferritin below 30 ng/mL, or haemoglobin below 12.0 g/dL in women and 13.0 g/dL in men) until repleted
  • Severe hepatic impairment (Child-Pugh Class C, the most advanced grade of liver failure) or advanced renal impairment (estimated glomerular filtration rate below 30 mL/min/1.73 m²)
  • Children and adolescents under 18, for whom no dosing or safety data exist

Risk Mitigation Strategies

  • Stay within the trialled dose range: The human trials used 10 mg daily; the only controlled safety study covered 50 mg daily for 4 weeks. Exceeding 50 mg leaves the hormetic window that benefit depends on entirely uncharacterised.

  • Separate from iron and from iron-rich meals: Dosing at least 2 hours away from oral iron and from the largest plant-iron meal prevents the 50–70% suppression of non-heme iron absorption seen with comparable polyphenol loads.

  • Confirm iron status before starting: A baseline ferritin and transferrin saturation identifies the menstruating women, blood donors and endurance athletes in whom reduced iron absorption converts from theoretical to clinically relevant.

  • Recheck thyroid function at 6–8 weeks: Thyroid-stimulating hormone with free triiodothyronine catches the hormone-activation effect before it produces symptoms, and is essential for anyone on levothyroxine, whose dose may need reduction.

  • Dose away from narrow-margin medications: A 4-hour gap from CYP3A4 and efflux-pump substrates reduces the unpredictable exposure changes that could cause either toxicity or treatment failure with tacrolimus, ciclosporin or digoxin.

  • Time away from hard training blocks: Taking kaempferol on rest days or at least 3 hours after a key endurance session preserves the post-exercise redox signalling that drives mitochondrial adaptation.

  • Stop before surgery or invasive dental work: Discontinuing 7 days ahead removes the additive platelet-inhibitory contribution, the same interval conventionally applied to other flavonol and fish-oil supplements.

  • Treat pregnancy as a stop condition: Discontinuing on a positive pregnancy test, or when actively trying to conceive, avoids fetal progenitor exposure implicated in the chromosomal-translocation findings.

Therapeutic Protocol

  • Core regimen: 10 mg of kaempferol aglycone (the sugar-free form) orally once daily, the dose used in every published human efficacy trial. This protocol was developed by the research institutes of Otsuka Pharmaceutical, which manufactures the preparation.

  • Competing approach, food-first: Obtain 20–40 mg daily from capers, kale, endive, tea, broccoli and beans rather than capsules. This lineage traces to the Zutphen and Rush cohort investigators, whose data are dietary rather than supplemental.

  • Competing approach, high-dose: 50 mg daily for 4 weeks is the only supplemental dose formally safety-tested. No efficacy trial has used it, and the hormesis literature argues against assuming more is better.

  • Best time of day: Morning with a fat-containing meal. Plasma concentration peaks near 5.8 hours, so morning dosing places peak exposure across the active part of the day; the exercise trials dosed before activity.

  • Half-life: No terminal half-life has been published for humans. Absorption peaks at about 5.8 hours and roughly 2% of a dose appears in urine within 24 hours, consistent with clearance inside a day.

  • Single versus split dosing: Single daily dosing is what the trials tested and what the long absorption peak supports. Splitting 50 mg into two 25 mg doses is a reasonable tolerability measure but has no supporting data.

  • Genetic considerations: Reduced-function UGT1A1, SULT1A1 or ABCG2 variants raise exposure several-fold from an identical dose. Anyone with a known slow-conjugator genotype, or with Gilbert’s syndrome (an inherited mild reduction in UGT1A1 activity), has reason to start lower.

  • Sex-based considerations: No trial has reported sex-stratified dosing. Women have lower average body mass and lower iron reserves, which argues for the 10 mg dose rather than 50 mg and for closer attention to iron status.

  • Age considerations: The observational benefit is concentrated in adults over 60, and only the 4-week safety trial enrolled that age band. In that group the 10 mg dose plus medication review before starting is the defensible position.

  • Baseline biomarkers that shape dosing: Ferritin, thyroid-stimulating hormone, liver enzymes and high-sensitivity C-reactive protein. Low ferritin or a suppressed thyroid-stimulating hormone argues for deferral; high inflammatory markers identify where response is most likely.

  • Pre-existing conditions that shape dosing: Treated hypothyroidism, anticoagulation, hormone-sensitive cancer and significant hepatic or renal impairment each warrant either avoidance or the lowest dose with scheduled monitoring rather than the standard regimen.

Discontinuation & Cycling

  • Intended duration: Open-ended use is unsupported. The longest human exposure studied is 4 weeks, so a defined 8–12 week trial followed by reassessment against baseline markers matches the evidence better than indefinite use.

  • Withdrawal effects: None reported. No trial recorded rebound symptoms on stopping, and the short residence time makes a withdrawal syndrome implausible; the intracellular thyroid-enzyme effect persisted 24 hours in cell work.

  • Tapering: Not applicable at these doses. Abrupt discontinuation is how every trial ended, including the crossover designs with 7-day washout periods, and no taper protocol has been described.

  • Cycling rationale: Plausible but untested. Hormetic compounds tend toward adaptive tolerance, so cycles of 8–12 weeks on and 4 weeks off are a reasonable hedge; no trial has compared continuous with intermittent dosing.

  • Washout interval: The crossover trials used 7 days between arms, which is the only empirically grounded washout figure and a sensible minimum before judging whether an observed effect was genuinely attributable.

  • Stop conditions: Discontinue on pregnancy, before surgery, on starting endocrine cancer therapy or topoisomerase-targeted chemotherapy, or if liver enzymes, thyroid-stimulating hormone or ferritin move outside their baseline range.

Sourcing and Quality

  • Aglycone versus glycoside: Products differ fundamentally. The trialled material is kaempferol aglycone, the free form; plant extracts deliver glycosides such as astragalin and kaempferitrin, whose absorption depends on the attached sugar.

  • Verify milligrams of kaempferol, not extract weight: A label reading “500 mg extract, 20% flavonoids” may contain under 20 mg of kaempferol. Only a stated aglycone content permits comparison with the 10 mg trial dose.

  • Botanical source matters: Published human material came from horseradish (Armoracia rusticana) leaves. Other commercial routes are Sophora japonica buds, Ginkgo biloba leaf and goji (Lycium barbarum) leaf, whose extract has a published toxicology evaluation (Lee et al., 2023).

  • Third-party testing: No stand-alone kaempferol product currently carries NSF Certified for Sport or USP Verified marks. In their absence, a batch-specific certificate of analysis confirming purity by high-performance liquid chromatography is the minimum.

  • Contaminant screening: Flavonol extracts from leaves concentrate heavy metals and pesticide residues. A certificate covering lead, cadmium, arsenic and mercury against California Proposition 65 limits is the relevant benchmark for leaf-derived material.

  • Reputable suppliers: The only preparation with published human trial data is Otsuka Pharmaceutical’s kaempferol aglycone, sold in Japan. Western products are unbranded extracts, so supplier choice rests on documentation rather than reputation.

  • Avoid Ginkgo biloba extract as a kaempferol source: Its kaempferol content is incidental and variable, it carries its own bleeding and terpene-lactone considerations, and independent testing has repeatedly found a majority of ginkgo products misrepresenting content.

Practical Considerations

  • Time to effect: Two timescales. Exercise and cardiopulmonary effects appeared within hours of a single dose; activity, sleep and symptom changes emerged over 2–4 weeks. Any cognitive or mortality signal is an intake pattern over years.

  • Common pitfall, confusing extract with compound: Buying a flavonoid blend or ginkgo extract and assuming a trialled dose has been taken. The trials used purified aglycone at a precisely stated 10 mg.

  • Common pitfall, dose escalation: Treating kaempferol like a linear-dose nutrient. The hormesis literature predicts reversal above an optimum, and no efficacy data exist above 10 mg daily.

  • Common pitfall, crediting food content: Capers and kale are far richer per 100 g than broccoli, but glucoside form and cooking determine absorption. Food-content tables overstate what reaches circulation.

  • Regulatory status: Marketed as a dietary supplement in the United States and a food-for-specified-health-use ingredient in Japan. It is not an approved medicine anywhere, so no prescribing information, no required potency verification and no adverse-event reporting obligation apply.

  • Cost and accessibility: Neither expensive nor scarce. Oral capsules typically cost under one United States dollar per day, and the equivalent intake from tea, kale and capers costs nothing beyond an ordinary vegetable budget.

  • Funding and payer landscape: No insurer or health system covers kaempferol, and the comparison is a capsule against vegetables, so no payer-driven bias exists. The bias present is commercial: one manufacturer funded every positive trial.

Interaction with Foundational Habits

  • Sleep: Potentiating and indirect. A 2-week crossover trial reported an improved wearable sleep score alongside a fall in sleeping heart rate and a rise in beat-to-beat heart-rate variability, consistent with greater parasympathetic tone. The effect may be secondary to increased daytime activity rather than direct. Morning dosing is what was tested.

  • Nutrition: Direct and bidirectional. Absorption improves with a fat-containing meal, while the same meal context creates the iron-binding problem, so dosing away from iron-rich plant foods matters. A diet already supplying capers, kale, endive, tea, broccoli and beans delivers a meaningful baseline intake that supplementation adds to rather than replaces.

  • Exercise: Potentiating acutely, potentially blunting chronically. Single doses lowered oxygen cost, heart rate and muscle-damage markers during hard efforts in trained men. Against that, chronic antioxidant dosing around training has suppressed mitochondrial adaptation markers in other compounds, so dosing on rest days or well after key sessions is the cautious arrangement.

  • Stress management: Indirect. No trial measured cortisol or a stress-response endpoint. The observed rise in heart-rate variability is a recognised marker of parasympathetic activity and therefore of stress resilience, but it was a secondary finding in one small trial and does not establish an effect on the stress axis itself.

Monitoring Protocol & Defining Success

Baseline testing before a first dose serves two purposes: identifying the people in whom kaempferol’s known actions become clinically relevant, and creating the comparison point without which any later change is uninterpretable. Because no established biomarker responds to kaempferol specifically, the panel below screens the organ systems its mechanisms touch — liver, thyroid, iron handling, glucose regulation and inflammation — rather than tracking the compound itself. Ongoing monitoring follows the same panel at 6–8 weeks, again at 6 months, then every 6–12 months while use continues, with an extra thyroid check 6–8 weeks after any dose change and an international normalised ratio within 1–2 weeks for anyone anticoagulated. Success is defined by the subjective and wearable markers moving while every safety marker stays inside its baseline range.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
ALT / AST 10–26 U/L (women), 10–30 U/L (men) Detects hepatic stress from a concentrated botanical extract Alanine and aspartate aminotransferase (liver enzymes that leak into blood when liver cells are stressed). Conventional upper limits of 40–55 U/L are far looser. Fasting not required; avoid within 48 h of hard exercise, which raises AST
TSH, free T4, free T3 TSH 0.5–2.0 mIU/L; free T4 and free T3 in the upper third of the laboratory range Kaempferol upregulates the enzyme converting thyroid hormone to its active form TSH is thyroid-stimulating hormone (the pituitary signal to the thyroid); T4 and T3 are thyroxine and triiodothyronine (the storage and active hormones). Conventional TSH range extends to 4.5. Draw before 10:00 and before any levothyroxine dose
Ferritin + transferrin saturation Ferritin 50–150 ng/mL (men, postmenopausal women), 40–100 ng/mL (menstruating women); saturation 25–35% Flavonols inhibit non-heme iron absorption Ferritin is the iron-storage protein and rises with inflammation, so it must be read alongside high-sensitivity C-reactive protein. Conventional laboratory ranges start as low as 15 ng/mL, well below the functional floor. Recheck 8 weeks after starting in anyone menstruating or donating blood
hs-CRP Below 1.0 mg/L, ideally below 0.5 mg/L Primary readout of the anti-inflammatory mechanism claimed for kaempferol High-sensitivity C-reactive protein (a general marker of body-wide inflammation). Conventional cut-off is 3.0 mg/L. Defer during acute illness or within 72 h of intense exercise
Fasting glucose + HbA1c Glucose 75–85 mg/dL; HbA1c 4.8–5.3% Captures the glucose-lowering effect reported in rodent models and flags hypoglycaemia risk on sulfonylureas HbA1c is glycated haemoglobin (average blood sugar over about three months). Conventional targets are below 100 mg/dL and below 5.7%. Requires an 8–12 h fast for glucose
eGFR + cystatin C eGFR above 90 mL/min/1.73 m² Confirms clearance capacity and excludes the renal impairment that contraindicates use eGFR is estimated glomerular filtration rate (a calculated measure of kidney filtering capacity). Conventional laboratories flag only values below 60 mL/min/1.73 m². Creatinine-based estimates are distorted by high muscle mass; cystatin C is not
Complete blood count No established kaempferol-specific target; track change from the individual’s own baseline, with haemoglobin 13.5–15.0 g/dL (men) and 12.5–14.0 g/dL (women) as reference anchors The safety endpoint chosen by the ongoing pharmacokinetic trial, and the system implicated by the progenitor-cell findings A complete blood count enumerates red cells, white cells and platelets. Conventional haemoglobin ranges extend down to 13.0 g/dL in men and 12.0 g/dL in women. Pair with ferritin, since iron depletion shows in red-cell indices before haemoglobin falls

Qualitative and wearable markers to track alongside the panel:

  • Sleep quality and sleep latency, recorded nightly for 2 weeks before starting and through the trial period
  • Resting heart rate on waking, and overnight heart-rate variability, the two measures that moved most consistently in the human trials
  • Daily step count and spontaneous activity, which rose in the crossover trial and are easier to detect than any laboratory change
  • Perceived exertion at a fixed submaximal workload, the subjective counterpart to the reduced oxygen cost seen in the exercise trials
  • Energy levels, cognitive clarity and headache frequency, the symptom domains reported in the open-label pilot
  • Gastrointestinal comfort, since tolerability above 50 mg daily is entirely uncharacterised

Emerging Research

  • Kaempferol Absorption and Pharmacokinetics Evaluation: Open-label, single-arm study in 120 healthy adults aged 18–70 taking oral kaempferol for 8 days, measuring peak concentration, time to peak, exposure and the first published terminal half-life, with multi-omics profiling (NCT07322406).

  • Independence of that trial: Led by the University of Pittsburgh with Weill Cornell and the University of North Carolina as sites, it is the first non-industry-led kaempferol trial, though Otsuka Pharmaceutical is a named collaborator, so sponsor independence is partial.

  • Topical and dermatological use: A 60-participant non-randomised study of kaempferol-containing facial masks measuring skin biophysical properties (NCT07458334), and a completed 30-participant study of kaempferol gel on bone density around dental implants (NCT07156799).

  • Evidence that could strengthen the case: Replication of the exercise and sleep findings by groups with no commercial stake would convert the strongest current claim from single-sponsor to independent. The hormesis synthesis predicts an identifiable optimal dose that the pharmacokinetic trial could locate (Calabrese et al., 2025).

  • Evidence that could weaken the case: Whether chronic supplemental dosing reproduces the chromosomal translocations seen in human progenitor cells is unresolved and untested in people (Barjesteh van Waalwijk van Doorn-Khosrovani et al., 2007; Goodenow et al., 2020).

  • Mechanistic redirection underway: Rodent work now attributes the cognitive effect to gut microbiota remodelling, short-chain fatty acid production and intestinal barrier repair rather than direct brain action (Wang et al., 2026), which would change what human biomarkers are worth measuring.

  • Unanswered dose question: No trial has tested anything between the 10 mg efficacy dose and the 50 mg safety dose, and none has run beyond 4 weeks, leaving both the dose-response curve and chronic tolerability undefined.

Conclusion

Kaempferol is a common plant pigment that has only recently been tested in people as a concentrated supplement. The human evidence is narrow but real. Small randomised trials show that a single low dose reduces the oxygen and heart-rate cost of hard physical effort and extends time to exhaustion, and a two-week trial found better sleep quality alongside more spontaneous daily movement. Large population studies link higher habitual intake to slower mental decline, fewer deaths and less heart disease, though the cancer findings point in opposite directions from one study group to the next and cannot support a causal reading.

Against this, the safety record is thin rather than reassuring. One four-week trial at five times typical dietary intake found nothing wrong, and nothing longer exists. Laboratory work raises three unresolved questions: chromosome breaks in blood-forming cells, activation of thyroid hormone, and reversal of benefit at higher concentrations. Reduced iron absorption is the one practical drawback with solid human grounding, and it comes from research on related plant compounds rather than from kaempferol itself.

The quality of the evidence base deserves particular weight. Every positive human trial was designed, funded and conducted by a single company that sells the compound, and that company is also a collaborator on the first university-led trial now under way. Nothing in the findings is implausible, yet the whole favourable human record traces back to one commercial source.

Top - Benefits - Risks - Protocol